Fatty acid amides as potential circulating biomarkers for sarcopenia

• DOI: 10.1002/jcsm.13244
• Publication Date: 2023-05-02T00:05:05Z
• Authors: Ye An Kim; Seung Hun Lee; Jung‐Min Koh; Seung‐hyun Kwon; Young Lee; Han Jin Cho; Hanjun Kim; Su Jung Kim; Ji Hyun Lee; Hyun Ju Yoo; Je Hyun Seo
• Keywords: Metabolome; Catabolism

Abstract Background Sarcopenia is characterized by a progressive decrease in skeletal muscle mass and function with age. Given that sarcopenia associated various metabolic disorders, effective biomarkers for its early detection are required. We aimed to investigate the related elderly men perform experimental studies using metabolomics. Methods Plasma metabolites from 142 men, comprising group an age‐matched control group, were measured global metabolome profiling. Muscle plasma samples aging mouse model of sarcopenia, as well cell media lysates during myoblast differentiation, analysed based on targeted Based these results, fatty acid amides quantified human tissues. The association amide levels parameters was evaluated. Results Global profiling showed significantly different (all P s < 0.01). Consistent results plasma, decreased but not tissue. In addition, increased differentiation. Targeted docosahexaenoic ethanolamide (DHA EA) ( = 0.016) sarcopenia. DHA EA level positively correlated such index (SMI) handgrip strength (HGS) 0.001, respectively). area under receiver‐operating characteristic curve (AUC) ≤ 4.60 fmol/μL 0.618 (95% confidence interval [CI]: 0.532–0.698). greater likelihood (odds ratio [OR]: 2.11, 95% CI: 1.03–4.30), independent HGS. addition age HGS improved AUC 0.620 0.691 0.0497). Conclusions Our study demonstrated potential circulating EA, particular, strongly strength, can be key metabolite become reliable biomarker Further research will provide insights into metabolomic changes relevant perspective.